Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blinded, Placebo-controlled, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of BBP-711 (ORF-229) in Healthy Adult Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Double-Blinded, Placebo-controlled, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of BBP-711 (ORF-229) in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BBP-711 (Primary)
  • Indications Primary hyperoxaluria; Renal calculi
  • Focus Adverse reactions; First in man
  • Sponsors Orfan Biotech

    • Most Recent Events

    • 04 Jul 2022 Results presented at the 37th Congress of the European Association of Urology
    • 27 Jun 2022 The data was shared in a feature oral presentation at European Society for pediatric nephrology (ESPN) 2022, taking place in Ljubljana, Slovenia.
    • 27 Jun 2022 According to Bridge Bio Pharma media release, the company has announced positive phase I data for BBP-711 in healthy volunteers supporting the development of the investigational therapy for patients with primary hyperoxaluria type-1 and recurrent kidney stone formers. The data was shared in a feature oral presentation at European Society for pediatric nephrology (ESPN) 2022, taking place in Ljubljana, Slovenia.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top